Skip to main content
SpringerLink
Log in

Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

We reported that IL-6 and IL-8 levels at the beginning of treatment are predictive indicators of response to therapy and prognosis of patients with recurrent breast cancer. The aim of this study was to investigate the trend of IL-6 and IL-8 levels in heavily pretreated patients with recurrent breast cancer.

Methods

Cytokine level trends in 12 patients heavily pretreated with anthracyclines were studied. Patients were divided into two groups according to the objective response. There were 5 partial response (PR)/no change (NC), and 7 progressive disease (PD) patients. Blood was taken every four weeks. IL-6 was measured by chemiluminescent enzyme immunoassay. IL-8 was measured by ELISA.

Results

The pretreatment level of IL-6 in the PR/NC group (11.0±2.1 pg/ml) was significantly lower than that (15.3±2.7 pg/ml) in the PD group. However, there was no difference in IL-8 level between the PR/NC group (12.5±5.5 pg/ml) and the PD group (11.5±1.1 pg/ml). IL-6 levels in the PR/NC group were maintained within normal levels or decreased to within normal levels after treatment, while levels of IL-6 in the PD group gradually increased until the time of patient death. A decrease in IL-8 level after treatment was observed in only one patient in the PR/NC group. Mild increase of IL-8 levels was observed in the PD group.

Conclusion

Continuous elevation of IL-6 levels indicates poor prognosis in heavily pretreated patients with recurrent breast cancer. Combination therapy including agents that reduce IL-6 levels will be a new strategy for aggressively treating recurrent breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

IL:

Interleukin

TNF:

Tumor necrosis factor

PR:

Partial response

NC:

No change

PD:

Progressive disease

ELISA:

Enzyme-linked immunosorbent assay

SEM:

Standard error of the mean

MPA:

Medroxyprogesterone acetate

5′DFUR:

Doxifluridine

References

  1. Kushner I: The acute phase response: An overview.Methods Enzymol 163:373–383, 1988.

    Article  PubMed  CAS  Google Scholar 

  2. Hirano T, Yasukawa K, Harada H,et al: Complementary DNA for a novel human interleukin (BSF-s) that induces B lymphocytes to produce immunoglobulin.Nature 324:73–76, 1986.

    Article  PubMed  CAS  Google Scholar 

  3. Kishimoto T: The biology of interleukin-6.Blood 74:1–10, 1989.

    PubMed  CAS  Google Scholar 

  4. Detmers PA, Lo SK, Olsen-Egbert E,et al: Neutrophil-activated protein 1/interleukin-8 stimulates the binding activity of the leukocyte adhesion receptor CDllb/CD18 on human neutrophils.J Exp Med 171:1155–1162, 1990.

    Article  PubMed  CAS  Google Scholar 

  5. Huber AR, Kunkel SL, Todd RF,et al: Regulation of transendothelial neutrophil migration by endogenous interleukin-8.Science 254:99–102, 1991.

    Article  PubMed  CAS  Google Scholar 

  6. Strassman G, Fong M, Kenney JS,et al: Evidence for the involvement of interleukin 6 in experimental cancer cachexia.J Clin Invest 89:1681–1684, 1992.

    Article  Google Scholar 

  7. Yasumoto K, Mukaida N, Harada A,et al: Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice.Cancer Res 55:921–927, 1995.

    PubMed  CAS  Google Scholar 

  8. Kajimura N, Iseki H, Tanaka R,et al: Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines.Cancer Chemother Pharmacol 38:48–52, 1996.

    Article  Google Scholar 

  9. Bobus VJ, Moll R, Gerharz DG,et al: Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin.Int J Cancer 77:415–423, 1998.

    Article  Google Scholar 

  10. Kurebayashi J, Otsuki T, Tang CK,et al: Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6.Br J Cancer 79:707–717, 1999.

    Article  PubMed  CAS  Google Scholar 

  11. Yokoe T, Lino Y, Takei H,et al: Changes of cytokines and thyroid function in patients with recurrent breast cancer.Anticancer Res 17:695–700, 1997.

    PubMed  CAS  Google Scholar 

  12. Zhan GJ, Adachi I: Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast cancer.Anticancer Res 19 (2B): 1427–1432, 1999.

    Google Scholar 

  13. Reiter Z, Chen L, Revel M,et al: Interleukin-6 protects ductal breast carcinoma cells from MHC-unrestricted cell-mediated cytotoxicity.Lymphokine Cytokine Res 11:175–181, 1992.

    PubMed  CAS  Google Scholar 

  14. Reed MJ, Topping L, Goldham NG,et al: Control of aromatase activity in breast cancer cells: The roll of cytokines and growth factors.J Steroid Biochem Molec Biol 44:589–596, 1993.

    Article  PubMed  CAS  Google Scholar 

  15. Purohit A, Ghilchik MW, Duncan L,et al: Aromatase activity and interleukin-6 production by normal and malignant tissues.J Clin Endocrinol Metab 80:3052–3058, 1995.

    Article  PubMed  CAS  Google Scholar 

  16. Asgeirsson KS, Olafsdottir K, Jonasson JG,et al: The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer.Cytokine 10:720–728, 1998.

    Article  PubMed  CAS  Google Scholar 

  17. Kishimoto T, Akira S, Taga T: IL-6 receptor and mechanism of signal transduction.Int J Immunopharmacol 14:431–438, 1992.

    Article  PubMed  CAS  Google Scholar 

  18. Kishimoto T: Interleukin-6 and its receptor in autoimmunity.J Autoimmun 5 Suppl A:123–132, 1992.

    Article  PubMed  Google Scholar 

  19. Haverty AA, Harmey JH, Redmond HP,et al: Interleukin-6 upregulates GP96 expression in breast cancer.J Surg Res 69:145–149, 1997.

    Article  PubMed  CAS  Google Scholar 

  20. Yokoe T, Lino Y, Takei H,et al: Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer.Anticancer Res 16:2069–2072, 1996.

    PubMed  CAS  Google Scholar 

  21. Pittman CS, Suda AK, Chambers JB,et al: Abnormalities of thyroid hormone turnover in patients with diabetes mellitus before and after insulin therapy.J Clin Endocrinol Metab 48:854–860, 1979.

    PubMed  CAS  Google Scholar 

  22. Wiersinga WM, Lie KI, Touber JL: Thyroid hormones in acute myocardial infarction.Clin Endoclinol 14:367–374, 1981.

    Article  CAS  Google Scholar 

  23. Lim VS, Fang VS, Kats AI,et al: Thyroid dysfunction in chronic renal failure.J Clin Invest 60:522–534, 1977.

    Article  PubMed  CAS  Google Scholar 

  24. Nomura S, Pittman CS, Chambers JB,et al: Reduced peripheral conversion of thyroxin to triiodothyronine in patients with hepatic cirrhosis.J Clin Invest 56:643–652, 1975.

    Article  PubMed  CAS  Google Scholar 

  25. Davidson SB, Dulchafsky SA, Diebel LN,et al: Effect of sepsis and 3,5,3’-triiodothyronine replacement on myocardial integrity during oxidant challenge.Crit Care Med 24:850–854, 1996.

    Article  PubMed  CAS  Google Scholar 

  26. Walker JD, Crawford FA, Mukherjee R,et al: Direct effect of acute administration of 3,5,3’-triiodo-L-thyronine on myocyte function.Ann Thorac Surg 58:851–856, 1994.

    Article  PubMed  CAS  Google Scholar 

  27. Morkin E, Pennock GD, Raya TE,et al: Studies on the use of thyroid hormone and a thyroid hormone analogue in the treatment of congestive heart failure.Ann Thorac Surg 56:S54–60, 1993.

    Google Scholar 

  28. Dulchafsky SA, Kenzenko SM, Saba AA,et al: Triiodothyronine (T3) supplementation maintains surfactant biochemical integrity during sepsis.J Trauma 39:53–58, 1995.

    Article  Google Scholar 

  29. Yamashita J, Hideshima T, Shirakusa T,et al: Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma.Cancer 78:2346–2352, 1996.

    Article  PubMed  CAS  Google Scholar 

  30. Kurebayashi J, Yamamoto S, Otsuki T,et al: Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells bothin vitro andin vivo; A possible mechanism of the anticachectic effect.Br J Cancer 79:631–636, 1999.

    Article  PubMed  CAS  Google Scholar 

  31. Yokoe T, Iino Y, Sugamata N,et al: Phase II trial of mitoxantrone, doxifluridine and medroxyprogesterone acetate as second-line treatment for anthracycline-resistant metastatic breast cancer.Anticancer Res 15:2303–2306, 1995.

    PubMed  CAS  Google Scholar 

  32. Iino Y, Yokoe T, Sugamata N,et al: A combination chemoendocrine therapy of mitoxantrone, doxifluridine, and medroxyprogesterone acetate for anthracycline-resistant advanced breast cancer.Cancer Chemother Pharmacol 41:243–247, 1998.

    Article  PubMed  CAS  Google Scholar 

  33. Purohit A, Singh A, Ghilchik MW,et al: Inhibition of tumor necrosis factor alpha-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol.Biochem Biophys Res Commun 261:214–217, 1999.

    Article  PubMed  CAS  Google Scholar 

  34. Sawada N, Ishikawa T, Fukase Y,et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.Clin Cancer Res 4:1013–1019, 1998.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Emergency and Critical Care Medicine, Gunma University School of Medicine, Gunma

    Takao Yokoe & Yuichi lino

  2. Second Department of Surgery, Gunma University School of Medicine, Gunma

    Yasuo Morishita

Authors
  1. Takao Yokoe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuichi lino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuo Morishita
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Yokoe, T., lino, Y. & Morishita, Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer 7, 187–190 (2000). https://doi.org/10.1007/BF02967458

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02967458

Key words

Search

Navigation